{"id":"W4283070056","doi":"10.3390/cancers14122985","title":"Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Children's Hospital; Children's Hospital of Eastern Ontario; London Health Sciences Centre; Centre Hospitalier Universitaire Sainte-Justine; C17 Council; University of Toronto; BC Children's Hospital; SickKids Foundation; Hospital for Sick Children","funders":"Garron Family Cancer Centre; Hospital for Sick Children","keywords":"Pazopanib; Medicine; Topotecan; Neutropenia; Pharmacokinetics; Adverse effect; Internal medicine; Pharmacology; Cmax; Oncology; Refractory (planetary science); Maximum tolerated dose; Tolerability; Chemotherapy; Gastroenterology; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008454585,0.0009900555,0.001311096,0.000221842,0.0004891278,0.0005444942,0.0009118041,0.0006711243,0.001571768],"category_scores_gemma":[0.0003792956,0.000287927,0.0007948417,0.0006698125,0.000741976,0.0002503686,0.0002895512,0.001957877,0.0002956227],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005571396,"about_ca_system_score_gemma":0.01144864,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1525263,"about_ca_topic_score_gemma":0.3365035,"domain_scores_codex":[0.9996701,0.00009509244,0.00001473495,0.00004609685,0.00007703912,0.00009690602],"domain_scores_gemma":[0.9994788,0.00004169292,0.00007302278,0.00001413708,0.00004945631,0.0003430134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4310916,0.047501,0.06087362,0.003819924,0.003737032,0.004479218,0.002018539,0.008296587,0.07190113,0.00215403,0.04231806,0.3218092],"study_design_scores_gemma":[0.5020742,0.2844901,0.1405423,0.0002882868,0.002437903,0.002924727,0.000479586,0.003414451,0.01120484,0.0003325311,0.05170796,0.0001030579],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856983,0.006071525,0.0003497784,0.001375889,0.00006142436,0.001223332,0.002083356,0.00008860414,0.003047684],"genre_scores_gemma":[0.9822061,0.00681538,0.00260508,0.001038983,0.0001107277,0.001115912,0.003704204,0.00002999327,0.002373652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8474737,"threshold_uncertainty_score":0.303277,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03863658546690084,"score_gpt":0.3691654049272565,"score_spread":0.3305288194603556,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}